Monday - November 16, 2026
CUHK landmark study identifies key oncogenic driver miR-21 in pancreatic cancer Pioneer Nb-RIBOTAC technology for dual-targeted attack to eliminate tumours
September 24, 2026
SHATIN, Hong Kong, Sept. 24 -- The Chinese University of Hong Kong posted the following news release:

* * *

CUHK landmark study identifies key oncogenic driver miR-21 in pancreatic cancer Pioneer Nb-RIBOTAC technology for dual-targeted attack to eliminate tumours

*

Pancreatic cancer, also known as the silent killer, is among Hong Kong's five deadliest cancers, with a dismal five-year survival rate of less than 10%. A research team from the . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products